


**Figure S1.** Differential expression of RBPs in clinically relevant neuroblastoma groupings (annotations focus on tumour-suppressive RBP families). This is a similar figure to 1A with different annotations used. CELF, TDRD and CPEB gene families have been annotated where possible. MNA = MYCN amplified, single = non-amplified MYCN status. RNF17 is a TDRD family member.



**Figure S2.** Differential expression of RBPs in clinically relevant neuroblastoma groupings (second cohort). The RBP gene list from Gerstberger et al. 2014 [16] was used to filter for RBP mRNAs and then compare (A) MYCN status of tumours or (B) Stages 4 and 4S. Both the analyses were displayed as a volcano plot using the two groups plotter option of the R2 the visualisation tool (<https://r2.amc.nl>). Versteeg cohort with the custom normalisation option was used on the R2 platform (GEO accession: GSE16476). mRNAs that were annotated in Figure 1 have been annotated where possible. mRNAs had to have a minimum of 20 expression units and be present in 20 tumours.

Statistical analysis was conducted with the Kruskal rank-based test, and FDR correction of p-values was performed. MNA = *MYCN* amplified, single = non-amplified *MYCN* status.



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).